Physician profile
Lance E Monroe
NPI 1083677058
$2,792.33
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $218 · 2021: $578 · 2022: $459 · 2023: $610 · 2024: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $494.44 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $331.10 | 2019-2024 | Farxiga, Breztri |
| Abbvie INC. | $267.66 | 2021-2024 | |
| Novo Nordisk INC | $258.10 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $201.91 | 2019-2024 | |
| Allergan, INC. | $138.78 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.54 | 2021-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $129.32 | 2021-2022 | |
| Amgen INC. | $94.94 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $90.82 | 2019-2020 | |
| Eisai INC. | $82.68 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.13 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $58.11 | 2019-2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.31 | 2023-2024 | |
| Astellas Pharma US INC | $47.26 | 2023-2024 | Veozah, Myrbetriq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $42.81 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $37.20 | 2019 | |
| Sanofi-Aventis U.S. LLC | $33.13 | 2020 | |
| Sanofi Pasteur INC. | $26.67 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $19.49 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.57 | 2024 | Dupixent |
| Sumitomo Pharma America, INC. | $16.27 | 2023 | Gemtesa |
| Janssen Pharmaceuticals, INC | $15.73 | 2019 | |
| Amarin Pharma, INC. | $15.31 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.21 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.73 | 2021 | |
| Assertio Therapeutics, INC. | $14.56 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.42 | 2023 | Rexulti |
| Boston Scientific Corporation | $12.63 | 2022 | |
| Esperion Therapeutics, INC. | $12.04 | 2021 | |
| Idorsia Pharmaceuticals US INC | $11.73 | 2022 | |
| Lilly USA, LLC | $11.27 | 2021 | |
| Corium, LLC | $9.46 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Monroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.